Update on Myelodysplastic Syndromes Classification and Prognosis

Area of Science:

• Hematology
• Oncology
• Stem Cell Biology

Background:

• Myelodysplastic syndromes (MDS) are clonal bone marrow (BM) disorders originating from aberrant hematopoietic stem cells and their niche.
• Patients experience progressive BM failure, symptoms, and a risk of transformation into acute myeloid leukemia.
• Traditional MDS diagnosis relies on morphology and blast percentage (French-American-British classification).

Purpose of the Study:

• To summarize current understanding of Myelodysplastic syndromes (MDS).
• To highlight advancements in MDS prognostication and molecular characterization.

Main Methods:

• Review of diagnostic criteria for MDS.
• Incorporation of the Revised International Prognostic Scoring System (IPSS-R).
• Integration of findings from deep sequencing technologies identifying molecular abnormalities in MDS.

Main Results:

• The Revised International Prognostic Scoring System offers improved prognostication over older methods.
• Deep sequencing has identified numerous molecular abnormalities associated with MDS.
• Understanding of MDS pathogenesis is evolving beyond morphology.

Conclusions:

• Modern approaches enhance MDS diagnosis and risk stratification.
• Molecular profiling is crucial for a comprehensive understanding of MDS.
• Continued research into MDS pathogenesis and molecular abnormalities is vital for therapeutic development.